Pancreatic Cancer Research

ResearcherDalian Medical UniversityActive in the last 2 years

Fangyue Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9783-4586; OpenAlex author ID A5101527783. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2020: 2 papers · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 9

  1. Lipid Nanoparticle-Based αHTRA1 mRNA Improves Pancreatic Ductal Adenocarcinoma Redox Microenvironment by Suppressing HTRA1/HIF-1 Signaling. Co-author DOI 10.1021/acs.bioconjchem.6c00013↗
  2. Carfilzomib relieves pancreatitis-initiated pancreatic ductal adenocarcinoma by inhibiting high-temperature requirement protein A1. Co-author DOI 10.1038/s41420-024-01806-w↗
  3. Botanical drugs and their natural compounds: a neglected treasury for inhibiting the carcinogenesis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/13880209.2024.2421759↗
  4. A prospective prognostic signature for pancreatic adenocarcinoma based on ubiquitination-related mRNA-lncRNA with experimental validation in vitro and vivo. Co-author DOI 10.1007/s10142-023-01158-1↗
  5. Identifying endoplasmic reticulum stress-related molecular subtypes and prognostic model for predicting the immune landscape and therapy response in pancreatic… Co-author DOI 10.18632/aging.205094↗
  6. DOK1/3/6 Serve as Potential Prognostic Biomarkers and Immunotherapy Targets for Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-907920/v1↗
  7. S100 Proteins in Pancreatic Cancer: Current Knowledge and Future Perspectives. Co-author DOI 10.3389/fonc.2021.711180↗
  8. The potential drug for treatment in pancreatic adenocarcinoma: a bioinformatical study based on distinct drug databases. Co-author DOI 10.1186/s13020-020-00309-x↗
  9. T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer? Co-author DOI 10.3389/fonc.2020.00382↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xufeng Tao · 4 shared papers, 2020–2026 · strength 0.84
  2. Deshi Dong · 3 shared papers, 2021–2026 · strength 0.71
  3. Dong Shang · 3 shared papers, 2023–2024 · strength 0.64
  4. Shilin Xia · 3 shared papers, 2020–2023 · strength 0.42
  5. Zhizhou Wang · 2 shared papers, 2023 · strength 0.37
  6. Xu Chen · 2 shared papers, 2023 · strength 0.37
  7. Hong Xiang · 2 shared papers, 2020–2024 · strength 0.37
  8. Dong Shang · 2 shared papers, 2021–2023 · strength 0.33
  9. Xinya Zhao · 1 shared paper, 2026 · strength 0.32
  10. Xiaonan Zhang · 1 shared paper, 2026 · strength 0.32
  11. Qi Zhou · 2 shared papers, 2020–2021 · strength 0.28
  12. Yu Wu · 1 shared paper, 2024 · strength 0.24
  13. Yunfei Dai · 1 shared paper, 2024 · strength 0.22
  14. Liang Zhao · 1 shared paper, 2024 · strength 0.22
  15. Biao Zhang · 1 shared paper, 2023 · strength 0.18
  16. Qihang Yuan · 1 shared paper, 2023 · strength 0.18
  17. Xueying Shi · 1 shared paper, 2023 · strength 0.18
  18. Yu Wu · 1 shared paper, 2021 · strength 0.16
  19. Dawei Deng · 1 shared paper, 2021 · strength 0.15
  20. Dong Shang · 1 shared paper, 2020 · strength 0.13
  21. Bing Qi · 1 shared paper, 2020 · strength 0.11
  22. Han Liu · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.